Company Overview
Astec LifeSciences Limited held its 32nd Annual General Meeting on July 31, 2026, where shareholders approved the FY26 financial results and key resolutions with overwhelming majority support exceeding 99.99%.
Financial Performance
For FY26, the company reported consolidated revenue of ₹45,322 lakh with a net loss of ₹8,088 lakh, showing significant improvement from the previous year's loss of ₹13,471 lakh. Key financial metrics demonstrated progress with EBITDA turning positive at ₹54 lakh compared to negative ₹6,058 lakh in FY25. The debt-equity ratio improved substantially from 2.36 to 1.15, reflecting successful balance sheet restructuring.
Capital Raising & Balance Sheet Strengthening
The company completed a rights issue of 26,69,951 equity shares at ₹890 per share, raising ₹23,622 lakh primarily to repay borrowings and for general corporate purposes. This capital infusion strengthened the company's financial position, with cash and cash equivalents increasing to ₹1,004 lakh from ₹57 lakh in the previous year.
Operational Highlights
Export sales grew 6.7% YoY while domestic sales surged 40.6%, with CDMO business contributing 52% of total sales. The company maintained its manufacturing operations across four facilities in Mahad, Maharashtra, and continued R&D activities at the Adi Godrej Center for Chemical Research. Employee strength stood at 471 permanent employees with operations spanning 19 export countries.
Governance & Management Changes
Significant board changes occurred during and after FY26, including the retirement of Mr. Nadir B. Godrej as Chairman and appointment of Mr. Vishal Sharma as Chairperson. Mr. Arijit Mukherjee was appointed as Executive Director and COO, while Mr. Deepak Ochani took over as CFO. The board composition includes 4 Independent and 4 Non-Independent Directors, with all directors maintaining high meeting attendance.
Contingent Liabilities & Risk Factors
The company faces substantial contingent liabilities of ₹17,876 lakh, primarily from excise duty demands (₹13,203 lakh), GST matters (₹826 lakh), income tax demands (₹449 lakh), and various other tax disputes. These ongoing litigations represent significant financial risk requiring continued monitoring.
ESG & Sustainability Initiatives
Astec LifeSciences maintained comprehensive ESG disclosures across nine principles, achieving EcoVadis Gold rating and maintaining Responsible Care certification since 2006. The company implemented zero liquid discharge facilities and avoided 3,700 Kg CO₂e emissions through waste diversion, demonstrating commitment to environmental sustainability.
Auditor Reports & Compliance
Statutory auditors B S R & Co. LLP provided an unqualified opinion, though revenue recognition was identified as a key audit matter requiring special attention. Secretarial and cost auditors also provided unqualified reports, confirming compliance with regulatory requirements.
Outlook & Strategic Positioning
Despite the improved performance, the company continues to operate at a loss with significant contingent liabilities. However, the successful rights issue, reduced debt levels, and improved operational metrics suggest a strategic turnaround is underway, positioning the company for potential recovery in the agrochemicals sector.